Middle East Flight Crisis Disrupts Millions as FDA Vaccine Chief Announces Exit

Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research (CBER), will depart the agency at the end of April 2026 — the second time he has left the post amid controversy. FDA Commissioner Marty Makary confirmed the departure, with Prasad set to return to his academic role at the University of California, San Francisco.

Prasad's tenure has been marked by contentious decisions that drew scrutiny from both scientific and patient advocacy communities. He initially refused to allow the FDA to accept for review Moderna's new mRNA flu vaccine — a decision reversed one week later under pressure. He also faced criticism over handling of rare disease drug approvals. He was previously removed as CBER director last July, only to be reinstated two weeks later before this final exit.

For consumers, the departure raises questions about the regulatory future of vaccines and biologics, including timing for updated COVID-19 boosters and next-generation flu shots for the 2026–27 season. Health officials emphasized that existing vaccine schedules remain in effect and the FDA is proceeding with a standard leadership transition. The agency's vaccine review processes are expected to continue without disruption while a replacement is identified.

The Global Wellness Summit's 2026 annual trends report has placed "neurowellness" at the top of its list, defining it as the use of technology and intentional practice to regulate the nervous system. The report argues that conventional fitness and nutrition routines have failed to address a deeper problem: modern life has placed most people in a near-constant state of chronic low-grade stress, with measurable consequences for sleep, mood, immunity, and long-term health.

The report identifies constant digital stimulation, blurred work-life boundaries, artificial light, social media, and global uncertainty as the primary drivers. This chronic activation contributes to anxiety, hormonal disruption, cognitive fog, and accelerated aging. Neurowellness responds by targeting the nervous system upstream — using both high-tech tools like vagus nerve stimulators, EEG-guided sleep devices, and neurofeedback platforms, and lower-tech practices like breathwork, yoga, touch therapy, and Feldenkrais movement.

The trend is already visible across the consumer landscape. Breathwork studios and cold plunge centers are opening in major cities, and wearables that track heart rate variability — a key nervous system indicator — are seeing record demand. Alongside this, the Summit's report highlights a broader shift toward community-based fitness, with run clubs, group competitions, and partner workouts replacing solitary gym sessions as the primary vehicle for consistent exercise. Experts say the two trends together signal a redefinition of what it means to be well in 2026.